VCRE Company Profile and Key Details

Average 10-day trading volume of 12.66 thousand shares is in line with the 3-month average of 12.66 thousand, indicating normal recent market interest.

Our AI price prediction model suggests that Vicore Pharma Holding AB stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Vicore Pharma Holding AB (NASDAQ:VCRE) closed at $12.65 USD, losing -$1.13 (-8.20%) from the previous close of $13.78. The stock is currently within 5% of its 52-week low $12.37 and $17.80. With a market capitalization of about $3.56 billion, Vicore Pharma Holding AB is classified as a mid-cap and shows lower-than-market volatility (beta ~0.15). Key stats such as the average daily volume over the past year has been around 167.22 thousand shares, volume is running light vs its 52-week average. Headquartered in Stockholm, None, Vicore Pharma Holding AB operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Ahmed Mousa, the company employs approximately 40 people and listed since July 02, 2026. Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications.